Étiquette : substance use disorders

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders, Francisco Navarrete et al., 2021

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders Francisco Navarrete, María Salud García-Gutiérrez, Ani Gasparyan, Amaya Austrich-Olivares and Jorge Manzanares Frontiers in Pharmacology, 2021, 12, Article 696010, 1-24. Doi : 10.3389/fphar.2021.626010   Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These facts hamper the clinical outcome and the quality of life of the patients supporting the importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant for the management of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s, or [...]

Lire la suite

CB2 Receptor Involvement in the Treatment of Substance Use Disorders, Francisco Navarrete et al., 2021

CB2 Receptor Involvement in the Treatment of Substance Use Disorders Francisco Navarrete, María S. García-Gutiérrez, Ani Gasparyan, Daniela Navarro and Jorge Manzanares Biomolecules, 2021, 11, 1556, 1-18. Doi : 10.3390/biom11111556   Abstract The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such [...]

Lire la suite

Learning to Let Go : A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance, Max Wolf et al., 2020

Learning to Let Go : A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance Max Wolff, Ricarda Evens, Lea J. Mertens, Michael Koslowski, Felix Betzler, Gerhard Gründer and Henrik Jungaberle Frontiers in Psychiatry, February 2020 | Volume 11 | Article 5, 1-13. doi : 10.3389/fpsyt.2020.00005   The efficacy of psychedelic-assisted therapies for mental disorders has been attributed to the lasting change from experiential avoidance to acceptance that these treatments appear to facilitate. This article presents a conceptual model that specifies potential psychological mechanisms underlying such change, and that shows substantial parallels between psychedelic therapy and cognitive behavioral therapy: We propose that in the carefully controlled [...]

Lire la suite

Novel Treatment Approaches for Substance Use Disorders : Therapeutic Use of Psychedelics and the Role of Psychotherapy, Michael Koslowski et al., 2021

Novel Treatment Approaches for Substance Use Disorders : Therapeutic Use of Psychedelics and the Role of Psychotherapy Michael Koslowski, Matthew W. Johnson, Gerhard Gründer, Felix Betzler Current Addiction Reports, 2021, 1-11. doi : 10.1007/s40429-021-00401-8   Abstract Purpose of Review : The use of psychedelics in a therapeutical setting has been reported for the treatment of various diagnoses in recent years. However, as psychedelic substances are still commonly known for their (illicit) recreational use, it may seem counterintuitive to use psychedelic therapy to treat substance use disorders. This review aims to discuss how psychedelics can promote and intensify psychotherapeutic key processes, in different approaches like psychodynamic and [...]

Lire la suite

Adolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler, 2020

Adolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler Drug and Alcohol Dependence, 2020, 210, 107960 Doi : 10.1016/j.drugalcdep.2020.107960   A B S T R A C T Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008–2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12–17 were used to model state treatment [...]

Lire la suite

Bibliographie : Mescaline et Peyotl, Dr Christian SUEUR, GRECC, avril 2020.

Bibliographie : Mescaline et Peyotl   Dr Christian SUEUR, GRECC, avril 2020.   1 - Mescaline et Peyotl, Histoire et culture : 1 - 2 2 - Neuro-Psychophysiologie de la mescaline : 3 - 4 3 - Pharmacologie de la mescaline : 5 - 7 4 - Toxicologie de la mescaline : 8 5 - Complications psychiatriques de la mescaline : 8 6 - Ethnopharmacologie du Peyotl : 9 - 11 7 - Mescaline et thérapie psychédélique : 12 - 13    

Lire la suite

COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response, Ali Farhoudian et al., 2020

COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response Ali Farhoudian, Alexander Baldacchino, Nicolas Clark, Gilberto Gerra, Hamed Ekhtiari, Geert Dom, Azarakhsh Mokri, Mandana Sadeghi, Pardis Nematollahi,  Maryanne Demasi, Christian G. Schütz, Seyed Mohammadreza Hashemian, Payam Tabarsi, Susanna Galea-singer, Giuseppe Carrà, Thomas Clausen, Christos Kouimtsidis, Serenella Tolomeo, Seyed Ramin Radfar, Emran Mohammad Razaghi An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper 29 mars 2020   Abstract : Coronavirus disease 2019 (COVID-19) is escalating across the world with higher morbidities and mortalities in certain vulnerable populations. People who use drugs (PWUD) are a marginalized and stigmatized group with [...]

Lire la suite

Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle, Gustavo Gonzalez-Cuevas et al., 2018

Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle Gustavo Gonzalez-Cuevas, Remi Martin-Fardon, Tony M. Kerr, David G. Stouffer, Loren H. Parsons, Dana C. Hammell, Stan L. Banks, Audra L. Stinchcomb and Friedbert Weiss Neuropsychopharmacology, 2018, 43, 2036–2045. Doi : 10.1038/s41386-018-0050-8   Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, has received attention for therapeutic potential in treating neurologic and psychiatric disorders. Recently, CBD has also been explored for potential in treating drug addiction. Substance use disorders are chronically relapsing conditions and relapse risk persists for multiple reasons including craving induced by drug contexts, susceptibility to [...]

Lire la suite

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders, Toby Lea et al., 2020

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders Toby Lea & Nicole Amada & Henrik Jungaberle & Henrike Schecke & Norbert Scherbaum & Michael Klein Psychopharmacology, 2020. Di : 10.1007/s00213-020-05477-0   Abstract Rationale : The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. Objectives : This paper examined subjective experiences of microdosing psychedelics to improve mental health or to cease [...]

Lire la suite

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic psychedelic Use : An Online Survey, Albert Garcia-Romeu et al., 2020

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic psychedelic Use : An Online Survey Albert Garcia-Romeu, Alan K. Davis, Earth Erowid, Fire Erowid, Roland R. Griffiths and Matthew W. Johnson Frontiers in Psychiatry, 2020, Vol 10, Article 955. Doi : 10.3389/fpsyt.2019.00955   Background : Observational data and preliminary studies suggest serotonin 2A agonist psychedelics may hold potential in treating a variety of substance use disorders (SUDs), including opioid use disorder (OUD). Aims : The study aim was to describe and analyze self-reported cases in which naturalistic psychedelic use was followed by cessation or reduction in other substance use. Methods : An anonymous online survey of [...]

Lire la suite